Virtually all models forecast that price competition will be less intense and price declines modest in comparison to the generics model. Many models, however, miss or underestimate factors and trends that push the biosimilars market in the other direction. These include, for example, sources of supply with lower variable costs, profit incentives for entry, participation of major pharma companies and an increase in comfort levels over time.

The OHE model varies from other models of biosimilar markets evolution by starting with transaction prices, rather than list prices, and factoring in the collection of 'Patient Safety Year' (PSY) data. These data will capture actual experience with a biosimilar, increasing the comfort level of prescribers and encouraging a gradual increase in market share. PSY data also have important implications for payers and governments, whose options also were outlined in this presentation.

The EuroQol Group's 27th Scientific Plenary will take place in mid-September. Researchers will report on several exciting developments in the EQ-5D, a measure of self-reported health widely used in research and in the NHS PROMs programme. Professor Nancy Devlin (OHE) and Professor Jan van Busschbach (Erasmus MC) are the joint Scientific Chairs.

On 16 July, OHE will present a Lunchtime Seminar by Prof Peter Zweifel, who will discuss his recent research on patients' willingness to pay for pharmaceuticals. Space is limited at this seminar.